CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
JI-101drug
Likely dose
JI-101 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00842335
NCT00842335Phase 2Completed
CompareCT.gov

A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors

Jubilant Innovation Ltd.·interventional·Posted Feb 12, 2009·Updated Jun 24, 2013

In Brief

A Phase 2 clinical trial evaluating JI-101 for Advanced Solid Tumors. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2010
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago

Interventions

JI-101drug

JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication